COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions

Abstract

The development of COVID-19 vaccines does not imply the end of the global pandemic as now countries have to purchase enough COVID-19 vaccine doses and work towards their successful rollout. Vaccination across the world has progressed slowly in all, but a few high-income countries (HICs) as governments learn how to vaccinate their entire populations amidst a pandemic. Most low- and middle-income countries (LMICs) have been relying on the COVID-19 Vaccines Global Access (COVAX) Facility to obtain vaccines. COVAX aims to provide these countries with enough doses to vaccinate 20% of their populations. LMICs will likely encounter additional barriers and challenges rolling out vaccines compared HICs despite their significant experience from the Expanded Programme on Immunisation (EPI). This study explores potential barriers that will arise during the COVID-19 vaccine rollout in lower-middle-income countries and how to overcome them. We conducted sixteen semi-structured interviews with national-level stakeholders from Ghana and Bangladesh (eight in each country). Stakeholders included policymakers and immunisation programme experts. Data were analysed using a Framework Analysis technique. Stakeholders believed their country could use existing EPI structures for the COVID-19 vaccine rollout despite existing challenges with the EPI and despite its focus on childhood immunisation rather than vaccinating the entire population over a short period of time. Stakeholders suggested increasing confidence in the vaccine through community influencers and by utilising local government accredited institutions such as the Drug Authorities for vaccine approval. Additional strategies they discussed included training more health providers and recruiting volunteers to increase vaccination speed, expanding government budgets for COVID-19 vaccine purchase and delivery, and exploring other financing opportunities to address in-country vaccine shortages. Stakeholders also believed that LMICs may encounter challenges complying with priority lists. Our findings suggest that COVID-19 vaccination is different from previous vaccination programs, and therefore, policymakers have to expand the EPI structure and also take a systematic and collaborative approach to plan and effectively rollout the vaccines.

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review

“…Vaccination has increased slowly worldwide. However, while few high-income countries' governments understand how to vaccinate their whole populations during the pandemic, most low-and middle-income countries have been trusting the COVID-19 Vaccines Global Access (COVAX) facility to acquire vaccines [75]. COVAX aims to require these countries with adequate doses to vaccinate 20% of their people.…”

Assessing Inequities in COVID-19 Vaccine Roll-Out Strategy Programs: A Cross-Country Study Using a Machine Learning Approach

“…Poor nations have to rely mainly on global collaborative co-financing vaccine procurement mechanisms, such as the "COVID-19 Vaccines Global Access" (COVAX) and the World Bank and the African Union's COVID-19 "Africa Vaccine Acquisition Task Team" (AVATT) platforms, aimed at supporting equitable and sustainable access to COVID-19 vaccines [12].…”

Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis

“…Meanwhile, immunomodulatory agents such as dexamethasone were found to only be effective among patients with severe disease receiving respiratory support, with little to no efficacy in patients with mild symptoms [ 4 ]. While vaccination remains one of the best strategies for the prevention of infections and disease progression, numerous obstacles—including vaccine hesitancy, logistical difficulties, and lack of access in low-to-middle income countries—continue to hamper its adoption [ 5 , 6 ]. Furthermore, older adults and those with comorbidities such as diabetes, obesity, and immunosuppression can present with atypical symptoms, have varying immunity from vaccination, and continue to be at high risk for hospitalization and mortality [ 7 , 8 ].…”